Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CIMETIDINE

All products: not a benefit

Other products in the same Health Canada class (A02B, A02BA) — coverage varies; not interchangeable

  • Famotidine (Pepcid): general benefit, Not a benefit
  • Nizatidine (Axid): general benefit
  • Ranitidine (Zantac): general benefit, Not a benefit
  • Misoprostol (Cytotec): general benefit, Not a benefit
  • Pantoprazole (Tecta): general benefit
  • Rabeprazole (Pariet): general benefit

7 more in the class list below

Tagamet · DIN 01916785 · 400mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-02-04 — choose a marketed DIN from the same-category list.Discontinued 2002-02-04 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-02-04 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-02-04 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tagamet · DIN 01916785 Manufacturer: Smith Kline Beecham Pharma Inc; listing date 1996-10-01 Health Canada: Cancelled post market since 2002-02-04 · brand TAGAMET 400 · ATC A02BA01 CIMETIDINE · form Tablet · route Oral · ingredients CIMETIDINE 400 MG · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Tagamet: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15833 · Verify on the e-Formulary ↗ (DIN 01916785)

Source record
DIN 01916785: Tagamet Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 564000011; group id 674; item number 1685; lccId None; manufacturer id SMJ Source form: Tab; strength: 400mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01916785 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15833
Interchangeable products
Cimetidine · DIN 00600059 · $0.2930
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2002-02-04 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

RANITIDINE HCL

· 23 products · Listed, not a benefit (3), General benefit (20) · strengths: 15mg/mL, 150mg, 300mg · Oral Sol, Tab

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

SUCRALFATE

· 4 products · General benefit · strengths: 1g/5mL, 1g · Oral Susp, Tab

LANSOPRAZOLE

· 16 products · Limited Use, codes 293, 295, 297, 401, 402 · strengths: 15mg, 30mg · DR Cap

LANSOPRAZOLE & CLARITHROMYCIN & AMOXICILLIN

· 2 products · Listed, not a benefit (1), Limited Use, codes 306, 307 (1) · strengths: 30mg & 500mg & 500mg · Tab/Cap Pk

OMEPRAZOLE

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (2), Limited Use, codes 293, 297, 401, 402 (13) · strengths: 10mg, 20mg · DR Cap

PANTOPRAZOLE SODIUM

· 30 products · Off-Formulary Interchangeable, not an ODB benefit (10), Limited Use, codes 293, 295, 297, 401, 402 (20) · strengths: 20mg, 40mg · Ent Tab

DEXLANSOPRAZOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 30mg, 60mg · DR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS CIMETIDINE (Cimetidine) is primary therapy - for conditions where the inhibition of gastric acid secretion is likely to be beneficial such as: • Duodenal ulcer therapy. • Non-malignant gastric ulcer therapy. • Prophylaxis of recurrent duodenal or gastric ulcer. • Gastroesophageal reflux disease. • Pathological hypersecretion associated with Zollinger-Ellison Syndrome, systemic mastocytosis and multiple endocrine adenomas. • Treatment of NSAID-induced lesions (ulcers, erosions) and gastrointestinal symptoms and prevention of their recurrence. • Adjunctive therapy in the management of cystic fibrosis in children. 1.1 Pediatrics Pediatrics (16 to 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of cimetidine in pediatric patients has been established. Therefore, Health Canada has authorized an indication for pediatric use. See 1 INDICATIONS, 4.2 Recommended Dose and Dosage Adjustment, and 8.1 Adverse Reaction Overview. 1.2 Geriatrics Geriatrics (>65 years of age): No data are available to Health Canada; however, evidence suggests that use in the geriatric population is associated with differe… https://pdf.hres.ca/dpd_pm/00064698.PDF PM date: DEC 31, 1982 Source product: CIMETIDINE; DIN 00487872; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Tagamet: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026